Outcome from surgery for vestibular schwannomas in children

British Journal of Neurosurgery

Volumn 23, Issue 3, 2009, Pages 226-231

  MacNally, Stephen P ^a   Rutherford, Scott A ^a   King, Andrew T ^a   Freeman, Simon ^b   Thorne, John ^a   Mawman, Deborah ^b   O'Driscoll, Martin P ^b   Evans, D G ^c   Ramsden, Richard T ^b  

^a HOPE HOSPITAL   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Auditory brain stem implant; Cochlear implant; Facial schwannoma; Hearing preservation; Neurofibromatosis type 2; Paediatric neurosurgery; Vestibular schwannoma

Indexed keywords

ADOLESCENT; ARTICLE; AUDIOGRAPHY; AUDITORY BRAIN STEM IMPLANT; AUDITORY REHABILITATION; CHILD; CLINICAL ARTICLE; COCHLEA PROSTHESIS; FACIAL NERVE; FEMALE; FOLLOW UP; GENETIC ANALYSIS; HEARING; HUMAN; MALE; NEURILEMOMA; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SPEECH DISCRIMINATION; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR VOLUME; VESTIBULAR SCHWANNOMA;

ADOLESCENT; AUDITORY BRAIN STEM IMPLANTS; AUDITORY THRESHOLD; CHILD; COCHLEAR IMPLANTS; CODON, NONSENSE; CRANIAL NERVE NEOPLASMS; FACIAL NERVE; FACIAL NERVE DISEASES; FEMALE; HEARING DISORDERS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; OUTCOME ASSESSMENT (HEALTH CARE); POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; SPEECH DISCRIMINATION TESTS;

EID: 67651173045     PISSN: 02688697     EISSN: 1360046X     Source Type: Journal    
DOI: 10.1080/02688690902968844     Document Type: Article

References (20)

1. Tos M, Stangerup SE, Caye-Thomasen P, Tos T, Thomsen J. What is the real incidence of vestibular schwannoma? Arch Otolaryngol Head Neck Surg 2004;130:216-20.
2. Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the north west of England over a 10-year period: Higher incidence than previously thought. Otol Neurotol 2005;26:93-7.
3. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-18.
4. Baser ME, Makariou EV, Parry DM. Predictors of vestibular schwannoma growth in patients with neurofibromatosis type 2. J Neurosurg 2002;96:217-22.
5. Mautner VF, Baser ME, Thakkar SD, Feigen UM, Friedman JM, Kluwe L. Vestibular schwannoma growth in patients with neurofibromatosis type 2: A longitudinal study. J Neurosurg 2002;96:223-8.
6. Otsuka G, Saito K, Nagatani T, Yoshida J. Age at symptom onset and long-term survival in patients with neurofibromatosis type 2. J Neurosurg 2003;99:480-3.
7. Rutherford SA, King AT. Vestibular schwannoma management: What is the 'best' option? Br J Neurosurg 2005;19:309-16.
8. Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: Substantial risks in certain tumour prone syndromes. J Med Genet 2006;43:289-94.
9. Freeman SR, Ramsden RT, Saeed SR, Alzoubi FQ, Simo R, Rutherford SA, King AT. Revision surgery for residual or recurrent vestibular schwannoma. Otol Neurotol 2007;28:1076-82.
10. Jacob A, Robinson LL, Jr., Bortman JS, Yu L, Dodson EE, Welling DB. Nerve of origin, tumor size, hearing preservation, and facial nerve outcomes in 359 vestibular schwannoma resections at a tertiary care academic center. Laryngoscope 2007;117:2087-92.
11. Mohr G, Sade B, Dufour JJ, Rappaport JM. Preservation of hearing in patients undergoing microsurgery for vestibular schwannoma: Degree of metal filling. J Neurosurg 2005;102:1-5.
12. Samii M, Matthies C, Tatagiba M. Management of vestibular schwannomas (acoustic neuromas): Auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Neurosurgery 1997;40:696-705; discussion 705-696.
13. Slattery WH, 3rd, Fisher LM, Hitselberger W, Friedman RA, Brackmann DE. Hearing preservation surgery for neurofibromatosis type 2-related vestibular schwannoma in pediatric patients. J Neurosurg 2007;106:255-60.
14. Yang J, Grayeli AB, Barylyak R, Elgarem H. Functional outcome of retrosigmoid approach in vestibular schwannoma surgery. Acta Otolaryngol 2008;128:881-6.
15. Martin TP, Tzifa K, Kowalski C, Holder RL, Walsh R, Irving RM. Conservative versus primary surgical treatment of acoustic neuromas: A comparison of rates of facial nerve and hearing preservation. Clin Otolaryngol 2008;33: 228-35.
16. Evans DG, Ramsden RT, Gokhale C, Bowers N, Huson SM, Wallace A. Should nf2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma? Clin Genet 2007;71:354-8.
17. Baser ME, Kuramoto L, Joe H, Friedman JM, Wallace AJ, Gillespie JE, Ramsden RT, Evans DG. Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: A population-based study. Am J Hum Genet 2004;75: 231-9.
18. Evans DG, Trueman L, Wallace A, Collins S, Strachan T. Genotype/phenotype correlations in type 2 neurofibromatosis (nf2): Evidence for more severe disease associated with truncating mutations. J Med Genet 1998;35:450-5.
19. Kluwe L, MacCollin M, Tatagiba M, Thomas S, Hazim W, Haase W, Mautner VF. Phenotypic variability associated with 14 splice-site mutations in the nf2 gene. Am J Med Genet 1998;77:228-33.
20. Ruttledge MH, Andermann AA, Phelan CM, Claudio JO, Han FY, Chretien N, Rangaratnam S, MacCollin M, Short P, Parry D, Michels V, Riccardi VM, Weksberg R, Kitamura K, Bradburn JM, Hall BD, Propping P, Rouleau GA. Type of mutation in the neurofibromatosis type 2 gene (nf2) frequently determines severity of disease. Am J Hum Genet 1996;59:331-42.